Table 2.
Trends over time between treatment groups for primary and secondary endpoints.
| Number of observations | Monthly change estimate | 95% CI | P value | |
|---|---|---|---|---|
| Primary endpoint | ||||
| % change in brain volume (SIENA) | 192 | −0.031 | −0.065, −0.002 | 0.065 |
| Secondary endpoints | ||||
| nGMV (cm3) | 177 | 0.34 | −1.49, 2.17 | 0.71 |
| nNAWMV (cm3) | 177 | 0.66 | −0.77, 2.09 | 0.36 |
| MSFC scores | 256 | −0.001 | −0.010, 0.009 | 0.86 |
| RNFL (micrometer) | 153 | −0.236 | −0.77, 0.30 | 0.39 |
| SDMT (number correct) | 124 | −0.01 | −0.14, 0.12 | 0.92 |
| Tertiary endpoints | ||||
| EDSS | 282 | −0.005 | −0.02, 0.01 | 0.56 |
| Low contrast vision (mean correct, 1.25%) | 270 | −0.134 | −0.33, 0.06 | 0.19 |
| MV (mm3) | 151 | −0.09 | −0.24, 0.06 | 0.22 |
| mfVEP (total global latency) (msec) | 100 | −0.26 | −0.91, 0.39 | 0.42 |
| nWMV (cm3) | 177 | 0.502 | −0.89, 1.89 | 0.48 |
Analyses are unadjusted for baseline imbalance.